[Skip to Content]
[Skip to Content Landing]
May 16, 1977

A New Star: How Brightly Will It Shine?

JAMA. 1977;237(20):2224. doi:10.1001/jama.1977.03270470060031

European pharmacologists have proved that the type 2, or H2, histamine receptor blockers are powerful suppressors of hydrochloric acid secretion. Most of these drugs provide excellent symptomatic and therapeutic means to relieve the pain and to speed the healing of gastric and duodenal ulcers. However, drugs such as burimamide and metiamide, although effective, were found to be bone marrow toxic. Cimetidine is a new drug in this group that was recently introduced into clinical use in Great Britain. It seems to be effective and safe and has not shown serious side effects or dangerous adverse reactions. Cimetidine has been well investigated in the laboratory and by immunologic and direct clinical studies.

At the Tenth Scandinavian Conference on Gastroenterology in September 1976, Bodemar and Walan1 reported that during the first week of treatment with cimetidine, there was a statistically significant decrease of diurnal HCl production in patients receiving cimetidine